Finch stock rises despite abandoning phase 3 trial, cutting ~95% workforce

Resignation concept.Businesswoman packing personal company belongings when she deciding resignation change of job or fired from the company.

pcess609/iStock via Getty Images

Finch Therapeutics (NASDAQ:FNCH) is discontinuing a phase 3 trial of its bacterial infection drug CP101 and reducing its workforce by ~95%.

The company noted that it will discontinue the late-stage study, dubbed PRISM4, of microbiome candidate CP101 in recurrent C. difficile

Read more here: Source link